Q-omics provides the consensus-scored CARNMT1 profile across patient tissues and cancer cell-line models. CARNMT1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CARNMT1 is differentially expressed in 15, with the highest sampling consensus in STAD. Additionally, CARNMT1 RNA expression shows 20,177 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, STAD, and ACC as cancer lineages where CARNMT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CARNMT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CARNMT1 survival associations across molecular data types. CARNMT1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CARNMT1 RNA expression–survival associations across cancer types. High CARNMT1 expression shows unfavorable associations in KIRP, LIHC, ACC and DLBC, but favorable associations in KIRC and BRCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for CARNMT1 RNA expression.
This table summarizes CARNMT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CARNMT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CARNMT1 shows lower tumor expression in KIRC and higher tumor expression in STAD, HNSC, LUSC, COAD and LUAD. The STAD box plot shows higher CARNMT1 RNA expression in tumor versus normal tissue (log2 FC = +1.084, t-test p < 0.001).
This table shows molecular features associated with CARNMT1 in patient tissues and cancer cell lines. In patient samples, CARNMT1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CARNMT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
